Our story

Vicore is an innovative Swedish clinical-stage pharmaceutical company dedicated to creating life-changing treatments in diseases where the Angiotensin II Type 2 Receptor (AT2R)  has a central role in stopping and reversing disease pathology.

The company was founded in the early 2000s based on the design and synthesis of buloxibutid (C21) by Professor Anders Hallberg’s group at Uppsala University.

We have a strong history of collaboration with the scientific community, leading to a wealth of preclinical data and ongoing clinical research in multiple indications to prove the AT2 receptor biology.

As a result of the pioneering work with buloxibutid, the first-in-class AT2 receptor agonist (ATRAG), the company now develops a portfolio of products for the treatment of rare lung diseases and following that, a clinical platform with novel compounds for a broad range of indications.

https://vicorepharma.com/wp-content/uploads/2023/02/vicore-tree-lung-graphic-update-3-e1676385891796-1.png